Cellular Efflux of cAMP and cGMP - A Question about Selectivity

Georg Sager* and Aina Westrheim Ravna

Department of Pharmacology, Institute of Medical Biology, University of Tromsø, N-9037 Tromsø, Norway

Abstract: The present paper reviews and discusses selectivity of ABCC4 (MRP4), ABCC5 (MRP5) and ABCC11 (MRP8) as cellular efflux pumps for cAMP and cGMP. These transporters are potential drug targets for selective modulation of cyclic nucleotide action.

Key Words: cGMP, cAMP, ABCC4, ABCC5, ABCC11, transport selectivity.

CYCLIC NUCLEOTIDES AS SECOND MESSENGERS

The discovery of cAMP as a second messenger to hormones and neurotransmitters by Sutherland and co-workers [1] and cGMP few years later [2], led to development of a number of drugs which became a part of modern pharmacotherapy. The impact of cyclic nucleotides in biology and pharmacology was summed up in a more recent review [3]. Knowledge about selectivity in the biokinetic processes (synthesis, enzymatic conversion and cellular efflux) may lead to the development of new and more specific drugs.

CELLULAR EFFLUX OF cAMP

Sutherland and co-workers showed that the pigeon erythrocytes extruded cAMP against a concentration gradient and that the transport was inhibited by probenecid, a non-specific organic anion transport inhibitor [4]. A variety of cells and tissue types, including erythrocytes, fibroblasts, cells from liver and heart, adrenocortical cells, astrocytoma cells, glioma cells, lymphoma cells, adipose tissue, islets of Langerhans, renal tubules and thyroid slices, extruded cAMP [5]. The transport was unidirectional and inhibited by agents such as metabolic inhibitors (iodoacetate, oligomycin and cyanide), inhibitors of membrane transport (probenecid and verapamil) and other compounds (vinblastine, papaverine and prostaglandins) [6-12]. The time course of intra- and extracellular cAMP levels showed different patterns after adenylate cyclase stimulation. Intracellular levels reached a peak after relative short period, whereas, extracellular levels increased linearly for a much longer time, before reaching a plateau [6, 8, 13]. A considerable difference between cell types in their ability to extrude cAMP has also been reported. The export from chromaffin cells limits the rise in cellular cAMP levels [14], whereas, efflux plays a minor role in the control of intracellular cAMP levels in osteoblast-like cells [15]. Values of the first order elimination constant vary between tissues from 0.14 to 0.014 min^{-1}, corresponding to a half-life of intracellular cAMP from a few minutes to almost one hour [16].

*Address correspondence to this author at the Faculty of Medicine, Institute of Medical Biology, Department of Pharmacology, University of Tromsø, N- 9037 Tromsø, Norway; Tel: +47-7764-4708; Fax: +47-7764-5310; E-mail: georg.sager@fagmed.uit.no

CELLULAR EFFLUX OF cGMP

Cellular cGMP efflux from pancreatic cells, liver and cerebellar slices, glioma and pheochromocytoma cells, vascular smooth muscle cells and endothelial cells showed unidirectional energy-dependent transport against a concentration-gradient and the transport was inhibited by probenecid [13, 17-20]. In airway epithelium, a vectorial cGMP transport was observed, and as much as one-half of the total cGMP was exported from the cells [21]. The apparent increase in total human platelet cGMP content observed after thrombin stimulation, was the result of an increase of cGMP in the extracellular compartment, due to cellular extrusion [22]. When soluble guanylate cyclase was stimulated and cyclic nucleotide phosphodiesterase inhibited in human platelets, intracellular cGMP levels increased almost 5-fold but nearly 20-fold on the extracellular side [23].

An experimental model with inside-out vesicles from human erythrocytes showed that cGMP transport was ATP- and temperature dependent, with K_m-values from 1 to 5 µM [24-26] with an ATPase [27]of m-type [28]. The transport of cGMP was directly linked to hydrolysis of ATP [29]. The low K_m cGMP transport was inhibited by well-known membrane transport modulating agents, like probenecid, sulfinpyrazone, verapamil and progestins [25, 26, 30, 31].

DIFFERENT CHARACTERISTICS OF CELLULAR cAMP AND cGMP EFFLUX

There are many evidences for selective cAMP and cGMP export. Even if intracellular cGMP levels were several times below those of cAMP, its urinary levels were within the same order of magnitude [32]. In a comparative study of endothelial and smooth muscle cells, the extracellular cGMP levels continued to rise after stimulation of guanylate cyclase for several hours, an observation in sharp contrast to the characteristics of cAMP accumulation after adenylate cyclase stimulation, with shorter duration and a peak nearly coincident with that of intracellular levels [13]. In kidney epithelial cells the polarization of cAMP and cGMP transporters and inhibitor (probenecid and nocodazole) potency was markedly different [33]. The first-order kinetic rate constants were 0.139 min^{-1} and 0.022 min^{-1} for cGMP and cAMP, respectively [34]. IBMX reduced the first order cGMP efflux rate six fold whereas that of cAMP was unchanged.

1389-5575/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd.

No competition was observed despite high intracellular cyclic nucleotide levels, after submaximal co-stimulation of guanylate cyclase and adenylate cyclase [34]. Together, these studies provide strong arguments for two separate transport systems.

ABCC4, ABCC5 AND ABCC11

Members of the organic anion ABCC transporters (ATP-Binding-Cassette transporter, subfamily C), previously called multidrug resistance associated proteins (MRP), are responsible for the cyclic nucleotide transport out of cells. The recognition and initial characterization of ABCC4 (MRP4) [35, 36], ABCC5 (MRP5) [35, 37, 38] and ABCC11 (MRP8) [39-41] showed that these efflux pumps have a P-glyco-protein-like core, consisting of two TMDs and two nucleotide-binding domains, distinct from other members of the ABCC subfamily which have an amino-terminal TMD (TMD_0).

ABCC4, ABCC5 AND ABCC11 AS TRANSPORTER PROTEINS FOR cGMP

Low and virtually identical K_m-values were reported for cGMP uptake into human erythrocyte inside-out vesicles [25, 26, 30, 31, 42, 43]. However, since both ABCC4 [42] and ABCC5 [44] coexist in human erythrocytes, the respective roles of these proteins were unclear, but direct evidence of ABCC5 being the low K_m transporter for cGMP was reported with a K_m-value of 2.1 µM in cells overexpressing ABCC5 [44]. Furthermore, cGMP transport was reduced after treatment of membrane extracts with antibodies against ABCC5 [45]. In agreement, ABCC5 operates as a cGMP-selective pump in pial arteriolar smooth muscle [46] and in pituitary cells [47]. Taken together, these reports show that ABCC5 transports cGMP with high affinity. The low affinity cGMP transport effectuated by ABCC5 [48] may be identical with the second transport component (K_m: 170 – 280 µM) reported for cGMP uptake into human erythrocyte inside-out vesicles [24, 30]. This process proved to be non-specific [30].

The features of cGMP transport by ABCC4 are less consistent. A study of human erythrocyte inside-out vesicles concluded that the cGMP transport had properties similar to those for MRP4 [42]. In addition to a minor high affinity transport component (K_m of 0.5-2.5 µM), a dominant low affinity component of cGMP transport with K_m values of 50-80 µM was reported. In a follow up study, both high affinity (3.3 µM) and low affinity (330 µM) cGMP transport were identified [43]. In cells overexpressing ABCC4 cGMP was transported with a K_m value for 180 µM [49]. The possibility exists that ABCC4 is responsible for the low affinity cGMP transport component (K_m-values of 170 – 280 µM) [24, 30] since ABCC4 is present in human erythrocytes [42]. In many studies with cells overexpressing ABCC4 low affinity transport for cGMP has been reported. High cGMP concentrations (>300 µM) were needed to reduce methotrexate transport markedly (53%) [50]. The maximal stimulation of ATPase activity by cGMP was modest (75% above basal) [51]. No sign of saturation of cGMP transport was observed for concentration up to 600 µM [48] and 1 mM cGMP was required to exceed 50 % inhibition of estradiol 17ß-glucuronide transported by ABCC4 [52].

However, some studies have also reported relatively high affinity cGMP transport by ABCC4. A K_m-value of 9.8 µM was calculated, but the affinity might have been overestimated, since the highest cGMP concentration tested was 25 µM [53]. A more recent study on human erythrocytes [54] showed a time- and concentration-dependent inhibition of cGMP transport by the irreversible serine protease inhibitor AEBSF. AEBSF blocked transport by ABCC4 but not by ABCG2. It has not been tested against ABCC5 and the data cannot be used to exclude a role for ABCC5 [54] since these cells contain both ABCC4 and ABCC5 [42, 44]. In smooth muscle cells wherein ABCC4 was silenced by siRNA, a clear increase (230%) in the intra- to extracellular cGMP ratio was observed [55] but this may rather reflect ABCC4 low affinity cGMP transport due to high intracellular cyclic nucleotide levels as a result of PDE inhibition by 100 µM IBMX.

In addition to member 4 and 5 of the ABCC family, overexpression of ABCC11 causes an increased cGMP extrusion [56]. Based on inhibition studies [57] the estimated IC_{50} values for cGMP are 25-50 µM. This shows that ABCC11 is transporting cGMP with medium to low affinity.

ABCC4, ABCC5 AND ABCC11 AS TRANSPORTER PROTEINS FOR cAMP

Assuming that low cGMP concentrations (1 µM) are mainly transported by ABCC5 in human erythrocyte inside-out vesicles, uptake was inhibited 15% by 100 µM and 50% by 300 µM cAMP [25, 42]. In cells with ABCC5 overexpression, cAMP caused low affinity inhibition of cGMP transport (K_i = 379 µM) [44] and of alaninyl-d4TMP transport (31% inhibition with 850 µM cAMP) [52]. No saturation of cAMP export from intact cells overexpressing ABCC4 was seen for intracellular concentrations up to 600 µM [48]. These studies show that ABCC5 transports cAMP with low affinity.

On the other hand, several studies support the idea that ABCC4 is a main cAMP transporter. Studies on cells overexpressing ABCC4 gave a) K_m-value of 45 µM [53], b) fourfold increase in ratio between extra- and intracellular cAMP levels after forskolin stimulation [58] and c) transported the cAMP analog (fluo-cAMP) with high affinity (K_m-value of 5.3 µM) [59]. An order of potency like PGA_1 > PGE1 > $PGF_{1\alpha}$ was reported for inhibition of an ABCC4 substrate (17-ß estradiol glucuronide) [60]. This is consistent with studies two decades ago wherein PGA_1 was an effective inhibitor of cAMP efflux [10, 61] with an order of potency like PGA_1 > PGB_1 > PGE_1 > $PGF_{1\alpha}$ [11, 62, 63]. When ABCC4 was silenced by siRNA a clear increase between intra- and extracellular cAMP levels (289%) appeared [55].

ABCC11 transports cAMP with moderate to low affinity [56, 57] with estimated IC_{50}-values (25 - 50 µM) similar to those of cGMP.

MOLECULAR MODELS OF cAMP ANDS cGMP

The planar structures of cGMP and cAMP are similar (Fig. (**1**)), but there is considerable degree of selectivity among protein kinase, some phosphodiesterases and cation



Fig. (1). Chemical structures of cAMP (panel A) and cGMP (panel B).

channels [64]. Differences in stereological conformations may account for this. In order to support this idea, molecular models were constructed based upon the crystal structures of cAMP bound to a cyclic nucleotide regulated potassium channel [65] and cGMP bound to a hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channel [66]. The energy minimized cAMP and cGMP crystal structures differed distinctly in spatial appearances and in the electrostatic potential surface (EPS) (Fig. (**2**)). When the cyclic nucleotides were flipped 180° along the y-axis, cAMP showed an oval, but linear shape (anti-conformation), whereas cGMP had a distinct hinge in the mid molecule (syn-conformation). Compared to the cAMP surface area which was neutral, cGMP had a prominent negative surface in the ribose-phosphate area. This shows that stereological requirements for selectivity exist.

CONCLUSIONS

The basis of development of new drugs is a selectivity for endogenous compounds between molecular targets. The existing data on cyclic nucleotides and ABCC transporters can be summarized like this: 1) ABCC4 is a selective moderate high affinity transporter for cAMP, 2) ABCC5 is a selective high affinity transporter for cGMP, 3) ABCC4 and ABCC5 have additionally a transport site with high K_m for both nucleotides, i.e. they are non-selective low affinity transporters and 4) ABCC11 is a non-selective low affinity transporter for cAMP and cGMP.



Fig. (2). Chemical structures of cAMP (panel **A** and **B**) and cGMP (panel **C** and **D**) superimposed on their respective EPS models. In panels B and D, the molecules are flipped 180° along the y-axis. The crystal structures of cAMP, bound to a cyclic nucleotide regulated potassium channel [65] and cGMP, bound to a hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channel [65] were used as input pdb structures for the X-windows graphical interface of the xleap shell scripts, and the Antechamber and tleap programs of the AMBER 8.0 program package. Atomic charges and atom types were assigned by the Antechamber program. The Sander program of the AMBER 8.0 program package was used for energy minimization of the ligands. The electrostatic potential surface (EPS) of cAMP and cGMP were calculated and visualized by the ICM program after converting the AMBER energy minimized structures to ICM objects *via* the ICM molecular editor.

In the structure formulas the different atoms are indicated as follows; carbon, oxygen, nitrogen, phosphor and hydrogen with yellow, red, blue, orange and grey, respectively. In the EPS-models blue, white and red areas indicate positive, neutral and negative areas.

ACKNOWLEDGEMENTS

This work was supported with grants from the Norwegian Cancer Society.

REFERENCES

[1] Sutherland, E.W.; RALL, T.W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. *J. Biol. Chem.*, **1958**, *232*, 1077-91.

[2] Ashman, D.F.; Lipton, R.; Melicow, M.M.; Price, T.D. Isolation of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate from rat urine. *Biochem. Biophys. Res. Commun.*, **1963**, *11*, 330-34.

[3] Beavo, J.A.; Brunton, L.L. Cyclic nucleotide research - still expanding after half a century. *Nat. Rev. Mol. Cell Biol.*, **2002**, *3*, 710-18.

[4] Davoren, P.R.; Sutherland, E.W. The effect of l-epinephrine and other agents on the synthesis and release of adenosine 3',5'-phosphate by whole pigeon erythrocytes. *J. Biol. Chem.*, **1963**, *238*, 3009-15.

[5] Barber, R.; Butcher, R.W. The egress of cyclic AMP from metazoan cells. *Adv. Cycl. Nucleotide Res.*, **1983**, *15*, 119-38.

[6] Penit, J.; Jard, S.; Benda, P. Probenecid sensitive 3',5'-cyclic AMP secretion by isoproterenol stimulated glial cells in culture. *FEBS Lett.*, **1974**, *41*, 156-60.

[7] King,C.D. ; Mayer,S.E. Inhibition of egress of adenosine 3',5'-monophosphate from pigeon erythrocytes. *Mol. Pharmacol.*, **1974**, *10*, 941-53.

[8] Doore, B.J.; Bashor, M.M.; Spitzer, N.; Mawe, R.C. Regulation of adenosine 3' :5'-monophosphate efflux from rat glioma cells in culture. *J. Biol. Chem.*, **1975**, *250*, 4371-72.

[9] Brunton, L.L.; Mayer, S.E. Extrusion of cyclic AMP from pigeon erythrocytes. *J. Biol. Chem.*, **1979**, *254*, 9714-20.

[10] Strewler, G.J. Release of cAMP from a renal epithelial cell line. *Am. J. Physiol.*, **1984**, *246*, C224-C230.

[11] Heasley, L.E.; Azari, J.; Brunton, L.L. Export of cyclic AMP from avian red cells. Independence from major membrane transporters and specific inhibition by prostaglandin A. *Mol. Pharmacol.*, **1985**, *27*, 60-65.

[12] Henderson, G.B.; Strauss, B.P. Evidence for cAMP and cholate extrusion in C6 rat glioma cells by a common anion efflux pump. *J. Biol. Chem.*, **1991**, *266*, 1641-45.

[13] Hamet, P.; Pang, S.C.; Tremblay, J. Atrial natriuretic factor-induced egression of cyclic guanosine 3':5'-monophosphate in cultured vascular smooth muscle and endothelial cells. *J. Biol. Chem.*, **1989**, *264*, 12364-69.

[14] Marley, P.D. ; Thomson, K.A. Regulation of cyclic AMP metabolism in bovine adrenal medullary cells. *Biochem. Pharmacol.*, **1992**, *44*, 2105-10.

[15] Ahlstrom, M. ; Lamberg-Allardt, C. Regulation of adenosine 3',5'-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells: role of cAMP-phosphodiesterase and cAMP efflux. *Biochem. Pharmacol.*, **1999**, *58*, 1335-40.

[16] Orlov, S.N. ; Maksimova, N.V. Efflux of cyclic adenosine monophosphate from cells: mechanisms and physiological implications. *Biochemistry (Moscow)*, **1999**, *64*, 127-35.

[17] Kapoor, C.L. ; Krishna, G. Hormone-induced cyclic guanosine monophosphate secretion from guinea pig pancreatic lobules. *Science*, **1977**, *196*, 1003-05.

[18] Tjörnhammar, M.L.; Lazaridis, G.; Bartfai, T. Cyclic GMP efflux from liver slices. *J. Biol. Chem.*, **1983**, *258*, 6882-86.

[19] Tjörnhammar, M.L.; Lazaridis, G.; Bartfai, T. Efflux of cyclic guanosine 3',5'-monophosphate from cerebellar slices stimulated by L-glutamate or high K+ or N-methyl-N'-nitro-N-nitrosguanidine. *Neurosci. Lett.*, **1986**, *68*, 95-99.

[20] Fiscus, R.R.; Robles, B.T.; Waldman, S.A.; Murad, F. Atrial natriuretic factors stimulate accumulation and efflux of cyclic GMP in C6-2B rat glioma and PC12 rat pheochromocytoma cell cultures. *J. Neurochem.*, **1987**, *48*, 522-28.

[21] Geary, C.A.; Goy, M.F.; Boucher, R.C. Synthesis and vectorial export of cGMP in airway epithelium: expression of soluble and CNP-specific guanylate cyclases. *Am. J. Physiol.*, **1993**, *265*, L598-L605.

[22] Wu, X.B.; Brune, B.; von Appen, F.; Ullrich, V. Efflux of cyclic GMP from activated human platelets. *Mol. Pharmacol.*, **1993**, *43*, 564-68.

[23] Radziszewski, W.; Chopra, M.; Zembowicz, A.; Gryglewski, R.; Ignarro, L.J.; Chaudhuri, G. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins. *Int. J. Cardiol.*, **1995**, *51*, 211-20.

[24] Sager, G.; Ørbo, A.; Pettersen, R.H.; Kjørstad, K.E. Export of guanosine 3',5'-cyclic monophosphate (cGMP) from human erythrocytes characterized by inside-out membrane vesicles. *Scand. J. Clin. Lab. Invest.*, **1996**, *56*, 289-93.

[25] Schultz, C.; Vaskinn, S.; Kildalsen, H.; Sager, G. Cyclic AMP stimulates the cyclic GMP egression pump in human erythrocytes: effects of probenecid, verapamil, progesterone, theophylline, IBMX, forskolin, and cyclic AMP on cyclic GMP uptake and association to inside-out vesicles. *Biochemistry*, **1998**, *37*, 1161-66.

[26] Sundkvist, E.; Jaeger, R.; Sager, G. Leukotriene C_4 (LTC_4) does not share a cellular efflux mechanism with cGMP: characterisation of cGMP transport by uptake to inside-out vesicles from human erythrocytes. *Biochem. Biophys. Acta*, **2000**, *1463*, 121-30.

[27] Vaskinn, S.; Sundkvist, E.; Jaeger, R.; Sager, G. The effect of Mg^{2+}, nucleotides and ATPase inhibitors on the uptake of [^{3}H]-cGMP to inside-out vesicles from human erythrocytes. *Mol. Membr. Biol.*, **1999**, *16*, 181-88.

[28] Pedersen, P.L. Multidrug resistance--a fascinating, clinically relevant problem in bioenergetics. *J. Bioenerg. Biomembr.*, **1995**, *27*, 3-5.

[29] Boadu, E.; Sager, G. ATPase activity and transport by a cGMP transporter in human erythrocyte ghosts and proteoliposome reconstituted membrane extracts. *Biochim. Biophys. Acta*, **2000**, *1509*, 467-74.

[30] Boadu, E.; Vaskinn, S.; Sundkvist, E.; Jaeger, R.; Sager, G. Inhibition by guanosine cyclic monophosphate (cGMP) analogues of uptake of [^{3}H]3',5'-cGMP without stimulation of ATPase activity in human erythrocyte inside-out vesicles. *Biochem. Pharmacol.*, **2001**, *62*, 425-29.

[31] Sundkvist, E.; Jaeger, R.; Sager, G. Pharmacological characterization of the ATP-dependent low K(m) guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes. *Biochem. Pharmacol.*, **2002**, *63*, 945-49.

[32] Steiner, A.L.; Pagliara, A.S.; Chase, L.R.; Kipnis, D.M. Radioimmunoassay for cyclic nucleotides. II. Adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in mammalian tissues and body fluids. *J. Biol. Chem.*, **1972**, *247*, 1114-20.

[33] Ardaillou, N.; Placier, S.; Ronco, P.; Ardaillou, R. Release of cyclic nucleotides from the apical and basolateral poles of cultured human glomerular epithelial cells. *Exp. Nephrol.*, **1993**, *1*, 253-60.

[34] Millul, V.; Prie, D.; GeniteauLegendre, M.; Verpont, M.C.; Baudouin, B.; Ronco, P.M. ANP-stimulated cGMP egression in renal principal cells: Abrogation of polarity by SV40 large T. *Am. J. Physiol.*, **1996**, *39*, C1051-C1060.

[35] Kool, M.; de Haas, M.; Scheffer, G.L.; Scheper, R.J.; van Eijk, M.J.; Juijn, J.A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. *Cancer Res.*, **1997**, *57*, 3537-47.

[36] Lee, K.; Belinsky, M.G.; Bell, D.W.; Testa, J.R.; Kruh, G.D. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. *Cancer Res.*, **1998**, *58*, 2741-47.

[37] McAleer, M.A.; Breen, M.A.; White, N.L.; Matthews, N. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. *J. Biol. Chem.*, **1999**, *274*, 23541-48.

[38] Belinsky, M.G.; Bain, L.J.; Balsara, B.B.; Testa, J.R.; Kruh, G.D. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. *J. Natl. Cancer Inst.*, **1998**, *90*, 1735-41.

[39] Bera, T.K.; Lee, S.; Salvatore, G.; Lee, B.; Pastan, I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. *Mol. Med.*, **2001**, *7*, 509-16.

[40] Tammur, J.; Prades, C.; Arnould, I.; Rzhetsky, A.; Hutchinson, A.; Adachi, M.; Schuetz, J.D.; Swoboda, K.J.; Ptacek, L.J.; Rosier, M.; Dean, M.; Allikmets, R. Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12,

tandemly duplicated on chromosome 16q12. *Gene*, **2001**, *273*, 89-96.

[41] Yabuuchi, H.; Shimizu, H.; Takayanagi, S.; Ishikawa, T. Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. *Biochem. Biophys. Res. Commun.*, **2001**, *288*, 933-39.

[42] Klokouzas, A.; Wu, C.P.; van Veen, H.W.; Barrand, M.A.; Hladky, S.B. cGMP and glutathione-conjugate transport in human erythrocytes. *Eur. J. Biochem.*, **2003**, *270*, 3696-708.

[43] Wu, C.P.; Woodcock, H.; Hladky, S.B.; Barrand, M.A. cGMP (guanosine 3',5'-cyclic monophosphate) transport across human erythrocyte membranes. *Biochem. Pharmacol.*, **2005**, *69*, 1257-62.

[44] Jedlitschky, G.; Burchell, B.; Keppler, D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. *J. Biol. Chem.*, **2000**, *275*, 30069-74.

[45] Boadu, E.; Sager, G. Reconstitution of ATP-dependent cGMP transport into proteoliposomes by membrane proteins from human erythrocytes. *Scand. J. Clin. Lab. Invest.*, **2004**, *64*, 41-48.

[46] Xu, H.L.; Gavrilyuk, V.; Wolde, H.M.; Baughman, V.L.; Pelligrino, D.A. Regulation of rat pial arteriolar smooth muscle relaxation *in vivo* through multidrug resistance protein 5-mediated cGMP efflux. *Am. J. Physiol. Heart Circ. Physiol.*, **2004**, *286*, H2020-H2027.

[47] Andric, S.A.; Kostic, T.S.; Stojilkovic, S.S. Contribution of multidrug resistance protein MRP5 in control of cGMP intracellular signaling in anterior pituitary cells. *Endocrinology*, **2006**, *147*, 3435-45.

[48] Wielinga, P.R.; van, d.H.I; Reid, G.; Beijnen, J.H.; Wijnholds, J.; Borst, P. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. *J. Biol. Chem.*, **2003**, *278*, 17664-71.

[49] van Aubel, R.A.; Smeets, P.H.; Van Den Heuvel, J.J.; Russel, F.G. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. *Am. J. Physiol.*, **2005**, *288*, F327-F333.

[50] Chen, Z.S.; Lee, K.; Walther, S.; Raftogianis, R.B.; Kuwano, M.; Zeng, H.; Kruh, G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. *Cancer Res.*, **2002**, *62*, 3144-50.

[51] Sauna, Z.E.; Nandigama, K.; Ambudkar, S.V. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. *J. Biol. Chem.*, **2004**, *279*, 49855-64.

[52] Reid, G.; Wielinga, P.; Zelcer, N.; de Haas, M.; van Deemter, L.; Wijnholds, J.; Balzarini, J.; Borst, P. Characterization of the Transport of Nucleoside Analog Drugs by the Human Multidrug Resistance Proteins MRP4 and MRP5. *Mol. Pharmacol.*, **2003**, *63*, 1094-103.

[53] Chen, Z.S.; Lee, K.; Kruh, G.D. Transport of cyclic nucleotides and estradiol 17-beta -d-glucuronide by multidrug resistance protein 4. resistance to 6-mercaptopurine and 6-thioguanine. *J. Biol. Chem.*, **2001**, *276*, 33747-54.

[54] de Wolf, C.J.; Yamaguchi, H.; van der Heijden, I; Wielinga, P.R.; Hundscheid, S.L.; Ono, N.; Scheffer, G.L.; de, H.M.; Schuetz, J.D.; Wijnholds, J.; Borst, P. cGMP transport by vesicles from human and mouse erythrocytes. *FEBS J.*, **2007**, *274*, 439-50.

[55] Sassi, Y.; Lipskaia, L.; Vandecasteele, G.; Nikolaev, V.O.; Hatem, S.N.; Cohen, A.F.; Russel, F.G.; Mougenot, N.; Vrignaud, C.; Lechat, P.; Lompre, A.M.; Hulot, J.S. Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. *J. Clin. Invest.*, **2008**, *118*, 2747-57.

[56] Guo, Y.; Kotova, E.; Chen, Z.S.; Lee, K.; Hopper-Borge, E.; Belinsky, M.G.; Kruh, G.D. MRP8 (ABCC11) is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines, 2'3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)-adenine *J. Biol. Chem.*, **2003**, *278*, 29509-14.

[57] Chen, Z.S.; Guo, Y.; Belinsky, M.G.; Kotova, E.; Kruh, G.D. Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). *Mol. Pharmacol.*, **2005**, *67*, 545-57.

[58] Lai, L.; Tan, T.M. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. *Biochem. J.*, **2002**, *361*, 497-503.

[59] Reichel, V.; Masereeuw, R.; Van Den Heuvel, J.J.; Miller, D.S.; Fricker, G. Transport of a fluorescent cAMP analog in teleost proximal tubules. *Am. J. Physiol. Regul.*, **2007**, *293*, R2382-R2389.

[60] Reid, G.; Wielinga, P.; Zelcer, N.; van, d.H., I; Kuil, A.; de Haas, M.; Wijnholds, J.; Borst, P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. *Proc. Natl. Acad. Sci. USA*, **2003**, *100*, 9244-49.

[61] Brunton, L.L.; Buss, J.E. Export of cyclic AMP by mammalian reticulocytes. *J. Cycl. Nucleotide Res.*, **1980**, *6*, 369-77.

[62] Brunton, L.L. ; Heasley, L.E. cAMP export and its regulation by prostaglandin A_1. *Methods Enzymol.*, **1988**, *159*, 83-93.

[63] Rindler, M.J.; Bashor, M.M.; Spitzer, N.; Saier jr, M.H. Regulation of adenosine 3':5'-monophosphate efflux from animal cells. *J. Biol. Chem.*, **1978**, *253*, 5431-36.

[64] Francis, S.H.; Blount, M.A.; Zoraghi, R.; Corbin, J.D. Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. *Front. Biosci.*, **2005**, *10*, 2097-117.

[65] Clayton, G.M.; Silverman, W.R.; Heginbotham, L.; Morais-Cabral, J.H. Structural basis of ligand activation in a cyclic nucleotide regulated potassium channel. *Cell*, **2004**, *119*, 615-27.

[66] Zagotta, W.N.; Olivier, N.B.; Black, K.D.; Young, E.C.; Olson, R.; Gouaux, E. Structural basis for modulation and agonist specificity of HCN pacemaker channels. *Nature*, **2003**, *425*, 200-05.

Received: 20 January, 2009 **Revised: 30 March, 2009** **Accepted: 31 March, 2009**